Abstract
BACKGROUND: Injectable fillers like PDLLA offer a novel approach to addressing lower eyelid rejuvenation. Despite their growing popularity, comprehensive studies on newer products like PDLLA are limited. AIMS: This study evaluates the efficacy and safety of PDLLA (Juvelook, VAIM Inc., Seoul, Korea) for treating tear trough deformities in Korean women, aiming to provide a long-term, minimally invasive solution for periorbital rejuvenation. MATERIALS & METHODS: A selected group of Korean women exhibiting tear trough deformities underwent treatment with PDLLA. Patients were assessed pre-treatment and followed up at 1 week, 1 month, and 6 months post-treatment, with outcomes measured by independent clinicians using the Hirmand classification and patient satisfaction scores. RESULTS: PDLLA demonstrated significant improvements in tear trough deformities with high patient satisfaction and minimal adverse effects. Follow-up results showed sustained improvements and no severe complications, indicating a safe profile for PDLLA. DISCUSSION: The study highlights PDLLA's potential advantages over traditional fillers, including longer-lasting effects and enhanced collagen production, suggesting it as a superior option for those seeking durable aesthetic improvements. CONCLUSION: PDLLA is an effective and safe treatment for periorbital rejuvenation in Korean women, providing lasting benefits and high patient satisfaction, warranting further comparative studies for broader applications.